Veracity Clinical Research contributes to global knowledge
Veracity Clinical Research is fortunate to contribute to world literature in the field of dermatology. In the past year, we have had numerous poster presentations in a number of publications and presented at various conferences around the world. Posters include:
ERASURE and FIXTURE study groups which were published in The New England Journal of Medicine
Daylight PDT with methyl aminolevulinate published in The British Journal of Dermatology
FIXTURE study group poster presented in Indiana USA in June
Daylight PDT poster presented at Australasian Dermatology Nurses Association's 13th National Conference
Poster presentation of Sukukimab presented at Winter Clinical Dermatology conference in Hawaii
Wu, J.J., Spelman, L., Tan, J.L. et al. Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results from the LIBERTY AD CHRONOS Clinical Trial. Published in Dermatology and Therapy, 28 January 2021. https://doi.org/10.1007/s13555-021-00487-y
A. Wollenberg, A. Blauvelt, E. Guttman-Yassky, M. Worm, C. Lynde, J.-P. Lacour, L. Spelman, N. Katoh, H. Saeki, Y. Poulin, A. Lesiak, L. Kircik, S.H. Cho, P. Herranz, M.J. Cork, K. Peris, L.A. Steffensen, B. Bang, A. Kuznetsova, T.N. Jensen, M.L. Østerdal, E.L. Simpson and on behalf of the ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). https://doi.org/10.1111/bjd.19574
Spelman, L., Rubel, D., Murrell, D.F., See, J.-A., Hewitt, D., Foley, P., Salmon, R., Kerob, D., Pascual, T., Shumack, S. and Fernandez-Penas, P. (2016), DL-PDT possible all year in Australia. Australasian Journal of Dermatology, 57: 24-28. https://doi.org/10.1111/ajd.12295
Zane L.T., Chanda S., Jarnagin K., Nelson D.B., Spelman L. & Stein Gold L.F. (2016) Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy VOL. 8, NO. 8. https://doi.org/10.2217/imt-2016-0023
Rubel DM, Spelman L, Murrell DF, See JA, Hewitt D, Foley P, Kerob D, Kerrouche N, Wulf HC, Shumack S. Daylight PDT with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional PDT in actinic keratosis treatment: a randomized controlled trial. May 24 2014. PMID: 24861492. https://doi.org/10.1111/bjd.13138
Rowe C, Spelman L, Oziemski M, Ryan A, Manoharan S, Wilson P, Daubney M, Scott J. Isotretinoin and mental health in adolescents: Australian consensus. Published: Australasian Journal of Dermatology, 28 November 2013. PMID: 24283385 / https://doi.org/10.1111/ajd.12117
Kaufmann R, Spelman L, Weightman W, Reifenberger J, Szeimies RM, Verhaeghe E, Kerrouche N, Sorba V, Villemagne H, Rhodes LE. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. British Journal of Dermatology, May 2008; 158(5):994-999. Epub 13 Mar 2008. PMID: 18341663
Hofman T, Cranswick N, Kuna P, Boznanski A, Latos T, Gold M, Murrell DF, Gebauer K, Behre U, Machura E, Olafsson J, Szalai Z, International Tacrolimus Ointment Study Group. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child 2006 Nov; 91(11):905-910. PMID: 16798785 / https://doi.org/10.1136/adc.2006.094276
Vinciullo C, Elliott T, Francis D, Gebauer K, Spelman L, Nguyen R, Weightman W, Sheridan A, Reid C, Czarnecki D, Murrell D. Photodynamic therapy with topical aminolaevulinate for ‘difficult-to-treat’ basal cell carcinoma. British Journal of Dermatology, April 2005; 152(4):765-772. PMID: 15840111
Thai KE, Fergin P, Freeman M, Vinciullo C, Francis D, Spelman L, Murrell D, Anderson C, Weightman W, Reid C, Watson A, Foley P. A prospective study of the use of cryosurgery for the treatment of actinic keratosis. International Journal Dermatology, September 2004; 43(9):687-692. PMID: 15357755
Noakes RR, Spelman L. Köbnerization in a woman with generalized lichen sclerosus. Australasian Journal of Dermatology May 2004: 45(2):144-145. PMID: 15068467
Martinez-Mir A, Glaser B, Chuang GS, Horev L, Waldman A, Engler DE, Gordon D, Spelman LJ, Hatzibougias I, Green J, Christiano AM, Zlotogorski A. Germline fumarate hydratase mutations in families with multiple cutaneous and uterine leiomyomata. J Invest Dermatol 2003 Oct; 121(4):741-744. PMID: 14632190
Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, Thai KE, Murrell D, Weightman W, Anderson C, Reid C, Watson A, Foley P. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003 Jun; 14(2):99-106. PMID: 12775317
Spelman L, Dicker T. Aquagenic pruritus relieved by tight fitting clothing. Australasian Journal of Dermatology, May 2001; 42(2):146. PMID: 11400693
Blauvelt A, Wollenberg A, Pink A, Worm M, Peris K, Armstrong A, Spelman L, Saeki H, Lynde C, Thyssen J P, Herranz P, Barbarot S, Abildgaard Steffensen L, Kuznetsova A, Simpson E. Assessing Long-term Maintenance of Efficacy With Tralokinumab Monotherapy in Patients With Moderate-to-severe Atopic Dermatitis: Combined Results From Two Phase 3, Randomized, Double-blind, Placebo-controlled Trials (ECZTRA 1 and 2). [Poster Link] American Academy of Dermatology Association Virtual Meeting Experience (AAD VMX), April 23−25, 2021.
Wang J., White J., Sansone K., Spelman L., Sinclair R., Yang S., Pan W., Wei Z., Connect Biopharma, San Diego, CA, USA and Suzhou, China; Veracity Clinical Research Pty Ltd. Woolloongabba, Queensland, Australia; Sinclair Dermatology, East Melbourne, Australia. A randomized, double-blind, placebo-controlled, multiple ascending dose study of the safety, pharmacokinetics and preliminary efficacy of CBP-201 in adult patients with moderate to severe atopic dermatitis (CBP-201AU002) [Poster Link] 29th EADV Congress, Vienna, 28th October - 1st November 2020.
Su J. C., Spelman L. J., Eichenfield L. F., Stein Gold L. F., Cha A., Graham D., Takiya L., Werth J. L., Zang C., Vlahos B. Efficacy and Safety of Crisaborole in Patients ≥3 Months of Age With Mild-to-Moderate Atopic Dermatitis (AD). [Poster Link] Presented at the Maui Derm Virtual Congress; June 24-27, 2020.
Langley R, Reich K, Griffiths C, Puig L, Spelman L, Rivas Zaldivar E, Wasel N, Salko T, Notter M, Helou S, Papavassilis C; for the FIXTURE Study Group. Secukinumab compared with placebo and etanercept in moderate-to-severe plaque psoriasis: a head-to-head comparison of 2 biologics in FIXTURE phase 3 study. [Poster] Society of Dermatology Physician Assistants Annual Summer Dermatology Conference, Indianapolis, Indiana, USA, May-Jun 2014.
Spelman L, Holland T, Davidson K. Best Practice Guidelines for Daylight Photodynamic Therapy (DL-PDT). [Poster] The Australian Dermatology Nurses Association 13th National Conference, Melbourne, Victoria, May 2014.
Langley R, Reich K, Griffiths C, Puig L, Spelman L, Rivas Zaldivar E, Wasel N, Salko T, Notter M, Helou S, Papavassilis. Secukinumab compared with placebo and etanercept: a head-to-head comparison of 2 biologics in a phase 3 study of moderate-to-severe plaque psoriasis (FIXTURE). [Poster] 10th Annual Maui Derm Conference, Maui, Hawaii, Jan 2014
Langley R, Reich K, Griffiths C, Puig L, Spelman L, Rivas Zaldivar E, Wasel N, Salko T, Notter M, Helou S, Papavassilis. Secukinumab compared with placebo and etanercept: a head-to-head comparison of 2 biologics in a phase 3 study of moderate-to-severe plaque psoriasis (FIXTURE). [Poster] 2014 Winter Clinical Dermatology Conference, Kona Coast, Hawaii, Jan 2014.
Stein-Gold L, Spelman L, Spellman MC, Hughes M, Zane LT. Safety and efficacy of AN2728 topical ointment, 2% and 0.5%, in a phase 2 dose-ranging study of adolescents with mild-to-moderate atopic dermatitis. [Poster] 2013 Australasian College of Dermatologists Biennial Spring Meeting, Cairns, Queensland, Oct 2013.
Langley R, Reich K, Griffiths C, Puig L, Spelman L, Rivas Zaldivar E, Wasel N, Salko T, Notter M, Helou S, Papavassilis C. Secukinumab compared with placebo and etanercept: The first 52-week head-to-head comparison of two biologics in a randomized, double-blind phase 3 study in subjects with moderate-to-severe psoriasis (FIXTURE). [Abstract] 22nd Congress of the EADV, Istanbul, Turkey, Oct 2013.
Spelman, L. Daylight PDT: a convenient, similarly effective, and nearly painless alternative to conventional PDT. [Oral Presentation] Dermatology Update 2013, Montreal, Quebec, Canada
Freeman M, Oakley A, Siller G, Rosen R, Salmon P, Spelman L, Shumack S, Rubel D, Birchall N, Katsamas J. Study to determine the optimal tolerated regimen of ingenol mebutate (PEP005) gel for actinic keratosis of the face or face and scalp. [Poster P2010] AAD Summer Meeting, Chicago, Illinois, USA, Jul/Aug 2008.
Spelman L. Metvix in AK’s other than face and scalp. [Poster] 7th EURO-PDT Annual Congress, Paris, France, Mar 2007.